potassium citrate (Renodyra® )

Status: Under consideration by AWMSG Scrutiny Panel
In adults for: The treatment of patients with kidney stones and hypocitraturia, or chronic calcium oxalate stones. The treatment and prevention of recurrent uric acid lithiasis with or without calcium lithiasis and cystine lithiasis.
Medicine details
Medicine name	potassium citrate (Renodyra® )
Formulation	1080 mg modified release tablets
Reference number	10641
Indication	As above
Company	Penlan Pharmaceuticals Limited
BNF chapter	Obstetrics, gynaecology & urinary tract disorders
Assessment type	Under consideration
Status	Under consideration by AWMSG Scrutiny Panel
Scrutiny Panel meeting date	06/08/2026